New corona commercial song 20189/25/2023 The spike protein sequences of XBB.1.5, XBB.1.16, and XBB.2.3 appear similar, with few amino acid differences. XBB.2.3 and other XBB sublineages could also continue to increase as the virus mutates. The current path of virus evolution suggests that XBB.1.16 could be dominant by fall 2023. Although XBB.1.5 has declined to less than 40% of presumed circulating virus in the United States, prevalence of XBB.1.16 is on the rise and XBB.2.3 is also slowly increasing. 1Īs of early July 2023, United States data on the evolution of SARS-CoV-2 indicated that XBB sublineages accounted for more than 95% of the circulating virus variants. 1 The FDA has advised manufacturers seeking to update their COVID-19 vaccines to develop vaccines with this same monovalent XBB.1.5 composition. Based on the evidence and other considerations presented, there was a preference for selection of XBB.1.5. 1įor the 2023-2024 formula of COVID-19 vaccines in the United States, the committee unanimously voted in favor of recommending a 2023-2024 formula update to a monovalent XBB lineage. The committee also reviewed timelines for manufacture of vaccines. Sublineages considered by the VRBPAC included XBB.1.5, XBB.1.16, and XBB.2.3.1 Evidence influencing their selection included virus surveillance and genomic data analysis, antigenic properties of viruses, findings from human serology studies from current vaccines, and findings from preclinical immunogenicity studies evaluating immune responses provided by candidate vaccines. The VRBPAC met on June 15, 2023, to discuss the strain composition for the 2023-2024 formula of COVID-19 vaccines in the United States.
0 Comments
Leave a Reply.AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |